Publication | Open Access

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

Eortc GcgMedicineCancer ManagementGynecologyFirst-line TreatmentAnti-cancer AgentCancer TreatmentTec Versus TcOncologyRadiation OncologyGynecology OncologyMolecular OncologyOvarian Cancer